Unlocking the potential of engineered immune cell therapy for solid tumors
Adoptive cell therapy has emerged as a promising approach for treating advanced solid malignancies. Genetic engineering techniques represent an exciting area of research for the development of cellular products with enhanced cytotoxicity, phenotype, and metabolism.
Authors
- Alena Gros (ORCID: https://orcid.org/0000-0002-1207-1880)
- Álvaro Urbano-Ispizúa (ORCID: https://orcid.org/0000-0002-7529-9399)
- Sònia Guedan
- Laura Angelats (ORCID: https://orcid.org/0000-0002-0410-5470)
- Aleix Prat (ORCID: https://orcid.org/0000-0003-2377-540X)
- Víctor Albarrán (ORCID: https://orcid.org/0000-0001-6356-2551)
- Julio Delgado
Institutions
- Breast Cancer Research Foundation (US)
- Hospital Clínic de Barcelona (ES)
- Vall d'Hebron Hospital Universitari (ES)
- Oryzon Genomics (Spain) (ES)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- Nature Communications
- Published
- 2025-01-29
- DOI
- https://doi.org/10.1038/s41467-025-56527-0
- Citations
- 20
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 20.91
Funders
- Universitat de Barcelona
- Institut d’Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona